Chimonanthus salicifolius essential oil protects against endotoxin-induced acute lung injury via suppression of β2 integrin-mediated neutrophil adhesion and chemotaxis.

Summary

In a murine ALI model, Chimonanthus salicifolius essential oil reduced edema, cytokines, and neutrophil activation while inhibiting NF-κB signaling. Mechanistically, its component eucalyptol directly bound β2 integrin (MST Kd ~19.5 μM), disrupted β2 integrin/ICAM-1 interactions, and curtailed neutrophil adhesion and chemotaxis, translating into in vivo lung protection.

Key Findings

• CSEO mitigated LPS-induced lung pathology, edema, inflammatory infiltration, and reduced MPO/NE activity and ROS, while inhibiting NF-κB activation.
• CSEO dose-dependently inhibited neutrophil adhesion to ICAM-1 and chemotaxis toward CXCL1 in vitro.
• Eucalyptol was identified as the active component: it bound β2 integrin (MST Kd ~19.5 μM), disrupted β2 integrin/ICAM-1 interaction, and suppressed neutrophil adhesion and chemotaxis.
• In vivo eucalyptol administration replicated CSEO’s protective effects, reducing ALI severity and neutrophil recruitment.

Clinical Implications

Targeting β2 integrin/ICAM-1 to dampen neutrophil trafficking could inform new therapies for ALI and potentially acute respiratory distress syndrome (ARDS) and other neutrophil-driven conditions, pending human validation and safety profiling.

Limitations

• Preclinical animal model; human efficacy, pharmacokinetics, and safety are unknown.
• Potential off-target effects of eucalyptol and optimal dosing/regimen were not established.

Future Directions

Evaluate β2 integrin-targeting by eucalyptol and analogs in additional neutrophil-driven disease models (e.g., viral pneumonia, ARDS), define PK/PD and safety, and explore structure–activity relationships to improve potency and specificity.